A recombinant collagen type XVII and a method for preparing the same

By constructing recombinant type XVII collagen with a specific amino acid sequence tandem in Pichia pastoris, the production difficulties of recombinant humanized type XVII collagen were solved, achieving efficient, stable expression and correct folding, and possessing a triple helix structure. This solved the problems of unstable expression and endoplasmic reticulum pressure in existing technologies.

CN120775034BActive Publication Date: 2026-01-13HEFEI KNATURE BIO PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511243912.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-09-02
Publication Date
2026-01-13
Estimated Expiration
2045-09-02

AI Technical Summary

Technical Problem

In the existing technology, the production of recombinant type XVII collagen is difficult, especially the synthesis of recombinant humanized type XVII collagen. Furthermore, there are challenges in functional region identification and screening, leading to unstable expression and endoplasmic reticulum stress, which prevents efficient production.

Method used

By selecting specific amino acid sequences for tandem and repetition, a nucleic acid molecule for recombinant type XVII collagen was designed. Using Pichia pastoris as the host cell, a non-viral vector such as a DNA plasmid was constructed for efficient expression. The expression system was optimized to solve the endoplasmic reticulum folding problem.

Benefits of technology

High expression levels of recombinant type XVII collagen were achieved with good stability and a triple helix structure. Electrophoresis showed no degradation bands, and circular dichroism chromatography revealed obvious helical characteristic peaks, thus solving the problems of expression instability and endoplasmic reticulum pressure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120775034B_ABST
    Figure CN120775034B_ABST
Patent Text Reader

Abstract

The application discloses a recombinant collagen type XVII and a preparation method thereof, and relates to the technical field of genetic engineering. The application provides a recombinant collagen type XVII. Compared with the prior art, the recombinant collagen type XVII provided by the application has high yield of Pichia pastoris engineering bacteria, is not easy to be degraded, and has a stable triple helix structure.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of genetic engineering, and in particular to a recombinant collagen XVII and a preparation method thereof. BACKGROUND

[0002] As a new biological medical material, collagen XVII shows great application potential in the fields of resisting skin aging, hair follicle stem cell regeneration, and preventing hair follicle aging. However, the content of collagen XVII in human and animal bodies is extremely rare, and it is difficult to extract, which cannot realize mass production. At the same time, animal-derived collagen products also have many potential safety hazards, such as poor water solubility, large batch differences, disease transmission hazards, and other serious problems, which greatly limit its clinical application. Compared with animal-derived collagen, recombinant collagen has more advantages in production method, safety, biocompatibility, cost, and sustainability.

[0003] Recombinant collagen XVII can be divided into three categories: recombinant human collagen XVII, recombinant humanized collagen XVII, and recombinant collagen XVII-like. Among them, recombinant human collagen XVII needs to contain the full-length amino acid sequence of human collagen XVII, which is difficult to produce. The gene coding sequence or amino acid sequence of recombinant collagen XVII-like is only partially consistent with human collagen, and the homology is low. Therefore, recombinant humanized collagen XVII is generally considered to be the best method for the recombinant production of human collagen XVII.

[0004] At present, the synthesis of recombinant humanized collagen XVII is difficult, and the identification and screening of functional regions are a problem. Recombinant expression of collagen XVII with human source characteristics needs to identify and screen functional regions with application potential, and does not contain self-antigen recognition sequences, so it is necessary to reasonably design the sequence, construct a suitable expression system and production process system. In addition, the amount of extracellular secreted by Pichia pastoris is small, so extracellular secretion expression is the main production method of foreign proteins in Pichia pastoris. In the process of signal peptide-guided secretion, the correct folding of proteins in the endoplasmic reticulum is very critical. The nascent peptide chain enters the endoplasmic reticulum in an unfolded state and is folded and assembled with the help of chaperones. However, efficient expression of foreign proteins can cause a large number of nascent peptide chains to accumulate and stay in the endoplasmic reticulum lumen without timely and correct folding, causing endoplasmic reticulum stress, and then activating the unfolded protein response (UPR). SUMMARY

[0005] (I) Technical problems solved

[0006] Therefore, one of the main objectives of this invention is to provide a recombinant type XVII collagen and its preparation method. Compared with the prior art, the recombinant type XVII collagen produced by Pichia pastoris engineered strains has a high yield, the protein is not easily degraded, and it has a stable triple helix structure.

[0007] (II) Technical Solution

[0008] To achieve the above objectives, the present invention provides a recombinant type XVII collagen (recombinant humanized type XVII collagen), whose amino acid sequence is compared with that of wild-type type XVII collagen:

[0009] Amino acids 567 to 808, 857 to 896, and 1399 to 1482 were selected and tandemly linked.

[0010] And / or select amino acids from position 567 to position 808, tandemly, and repeat twice;

[0011] And / or select amino acids 1399 to 1482 in series and repeat 4 times;

[0012] And / or select amino acids 857 to 896 and 1399 to 1482 in series and repeat 3 times;

[0013] And / or select amino acids 597 to 617, 621 to 638, 641 to 655, 695 to 715, 722 to 733, 902 to 923, 954 to 968, and 1438 to 1467, and repeat them in series three times.

[0014] The amino acid sequence of the wild-type XVII collagen has a Protein ID of NP_000485.3 in the NCBI database.

[0015] In one embodiment, the recombinant type XVII collagen, compared to the wild-type type XVII collagen amino acid sequence:

[0016] Amino acids 567 to 808, 857 to 896, and 1399 to 1482 were selected and tandemly linked.

[0017] Alternatively, amino acids from position 567 to position 808 can be tandemly repeated twice;

[0018] Alternatively, amino acids from position 1399 to position 1482 can be tandemly repeated four times.

[0019] Alternatively, amino acids 857 to 896 and 1399 to 1482 can be selected, tandemly, and repeated three times.

[0020] Alternatively, amino acids 597 to 617, 621 to 638, 641 to 655, 695 to 715, 722 to 733, 902 to 923, 954 to 968, and 1438 to 1467 can be selected, tandemly, and repeated three times.

[0021] In one embodiment, it is selected from:

[0022] (1): Recombinant type XVII collagen having the amino acid sequence shown in SEQ ID No. 1-5; or

[0023] (2): Recombinant type XVII collagen homologous to the amino acid sequence shown in SEQ ID NO. 1-5 or having 70-99% amino acid sequence identity; or

[0024] (3): Recombinant type XVII collagen derived from (1) or (2) by substitution, deletion or addition of one or more amino acids in the amino acid sequence of (1) or (2);

[0025] In one embodiment, the recombinant type XVII collagen amino acid sequence has the amino acid sequence shown in SEQ ID No. 5.

[0026] In another aspect, the present invention provides a nucleic acid molecule that encodes the aforementioned recombinant type XVII collagen.

[0027] In one embodiment, the nucleic acid molecule has the nucleotide sequences shown in SEQ ID NO. 6-10.

[0028] In one embodiment, the nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO.10.

[0029] In another aspect, the present invention provides a carrier comprising the above-described nucleic acid molecules.

[0030] In one embodiment, the vector includes a viral vector and / or a non-viral vector.

[0031] In one embodiment, the vector is a non-viral vector.

[0032] In one embodiment, the non-viral vector comprises one or a combination of DNA plasmids, nanoparticles, cationic polymers, extracellular vesicles, or liposomes.

[0033] In one embodiment, the non-viral vector is a DNA plasmid.

[0034] In one embodiment, the DNA plasmid further includes a second nucleic acid molecule.

[0035] In one embodiment, the second nucleic acid molecule is selected from nucleic acid molecules encoding KAR2, HAC1, ERO1, PDI1, WSC4, ERV29, Sec1, Sly1, SSA4(Sc), SSE1(Sc), KIN2, or CUP5.

[0036] In one embodiment, the DNA plasmid has the nucleotide sequences shown in SEQ ID No. 11-22.

[0037] In one embodiment, the second nucleic acid molecule is a nucleic acid molecule encoding KIN2.

[0038] In one embodiment, the DNA plasmid has the nucleotide sequence shown in SEQ ID No. 21.

[0039] In another aspect, the present invention also provides a cell comprising the aforementioned nucleic acid molecules and / or carriers.

[0040] In one embodiment, the cell is a Pichia pastoris cell.

[0041] (III) Beneficial Effects

[0042] This invention provides a recombinant type XVII collagen and its preparation method. Compared with the prior art, it has the following advantages:

[0043] 1. High expression level, reaching up to 1.22 g / L during shake flask culture.

[0044] 2. It has good stability, and the electrophoretic detection shows a single band with no degradation bands.

[0045] 3. It possesses a triple helix higher-order structure, and circular dichroism chromatographic detection results show obvious helical characteristic peaks. Attached Figure Description

[0046] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0047] Figure 1 This is a graph showing the results of nucleic acid electrophoresis detection of PCR products in Example 1.

[0048] Figure 2 This is a graph showing the expression detection of recombinant type XVII collagen in Example 1.

[0049] Figure 3 This refers to the expression level of recombinant type XVII collagen in the shake flask in Example 1.

[0050] Figure 4 This is a graph showing the results of nucleic acid electrophoresis detection of PCR products in Example 2.

[0051] Figure 5 This is a graph showing the expression detection of recombinant type XVII collagen in Example 2.

[0052] Figure 6 This refers to the expression level of recombinant type XVII collagen in the shake flask in Example 2.

[0053] Figure 7 This is the circular dichroism spectrum of recombinant type XVII collagen.

[0054] Figure 8 This is a scratch test result of recombinant type XVII collagen. Detailed Implementation

[0055] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0056] Terms and Definitions

[0057] As used herein, the terms "recombinant type XVII collagen" and "recombinant humanized type XVII collagen" are used interchangeably. The recombinant type XVII collagen disclosed in this invention may be recombinant type XVII collagen encoded by the sequences SEQ ID NO: 1-5 or homologous sequences (e.g., homologous sequences of proteins obtainable from databases or alignment software known in the art), variants, or modified forms that function with these recombinant type XVII collagens. For example, the recombinant type XVII collagen may be selected from:

[0058] (1): Recombinant type XVII collagen having the amino acid sequence shown in SEQ ID No. 1-5; or

[0059] (2): Recombinant type XVII collagen homologous to the amino acid sequence shown in SEQ ID NO. 1-5 or having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% amino acid sequence identity; or

[0060] (3): Recombinant type XVII collagen derived from (1) or (2) by substitution, deletion or addition of one or more amino acids in the amino acid sequence of (1) or (2).

[0061] The variant forms of recombinant type XVII collagen disclosed in this invention include (but are not limited to): deletion, insertion and / or substitution of one or more amino acids (typically 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10), and addition of one or more amino acids (typically up to 20, preferably up to 10, more preferably up to 5) at the C-terminus and / or N-terminus.

[0062] For example, in the art, substitution with amino acids of similar or comparable properties generally does not alter the function of recombinant type XVII collagen. Similarly, adding one or more amino acids to the C-terminus and / or N-terminus generally does not change the function of recombinant type XVII collagen; for instance, the recombinant type XVII collagen disclosed in this invention may or may not include the initial residues while still retaining its functional activity.

[0063] Random mutagenesis can be induced by radiation or exposure to mutagens, or the proteins or peptides mentioned in (3) above can be obtained by site-directed mutagenesis or other known molecular biology techniques.

[0064] As used herein, the terms “recombinant type XVII collagen gene,” “gene encoding recombinant type XVII collagen,” “gene encoding recombinant type XVII collagen,” or “nucleic acid molecule encoding recombinant type XVII collagen” are used interchangeably and all refer to a nucleotide sequence encoding the recombinant type XVII collagen disclosed in this invention, which may be, for example, the nucleotide sequence shown in SEQ ID NO: 6-10.

[0065] The genes disclosed in this invention can be selected from:

[0066] (1) A nucleic acid molecule having the nucleotide sequence shown in SEQ ID NO: 6-10; or

[0067] (2) Nucleic acid molecules that are similar to the sequence defined in (1) under strict conditions.

[0068] The full-length nucleotide sequence or fragments of the recombinant type XVII collagen gene disclosed in this invention can generally be obtained by PCR amplification, recombination, or artificial synthesis. For PCR amplification, primers can be designed based on the relevant nucleotide sequences disclosed in this disclosure, especially the open reading frame sequences, and commercially available cDNA libraries or cDNA libraries prepared using conventional methods known to those skilled in the art can be used as templates to amplify the relevant sequences. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then splice the fragments amplified from each amplification in the correct order.

[0069] It should be understood that the genes disclosed in this invention are preferably obtained from humans. Other genes obtained from other animals that are highly homologous to the species' genes (e.g., having more than 50%, preferably more than 55%, 60%, 65%, 70%, 75%, 80%, more preferably more than 85%, such as 85%, 90%, 95%, 98%, or even 99% or more sequence identity) are also within the scope of this preferred consideration. Methods and tools for comparing sequence identity are also well known in the art, such as BLAST.

[0070] As used herein, the terms "vector" and "recombinant expression vector" are used interchangeably, referring to bacterial plasmids, bacteriophages, yeast plasmids, animal cell viruses, mammalian cell viruses, or other vectors well known in the art. In short, any plasmid and vector can be used as long as it can replicate and remain stable within the host. An important characteristic of expression vectors is that they typically contain an origin of replication, a promoter, a marker gene, and translational control elements.

[0071] Methods well known to those skilled in the art can be used to construct expression vectors containing recombinant type XVII collagen coding sequences and suitable transcription / translation control signals. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. The DNA sequence can be efficiently ligated to an appropriate promoter in the expression vector to guide mRNA synthesis. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator. Vector expression systems are preferred in this invention.

[0072] In addition, the expression vector preferably contains one or more selective marker genes to provide phenotypic traits for selecting host cells for transformation, such as resistance to genipathic mycotoxin or bleomycin for yeast culture, or resistance to ampicillin or kanamycin for Escherichia coli.

[0073] Vectors containing the aforementioned appropriate DNA sequences and appropriate promoters or control sequences can be used to transform suitable host cells to enable them to express recombinant type XVII collagen. Host cells can be prokaryotic cells, such as bacterial cells; lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as animal cells. Representative examples include: *Escherichia coli*, *Streptomyces*, *Agrobacterium*; fungal cells such as yeast; and animal cells. In this invention, *Pichia pastoris* cells are preferably used as the host cell.

[0074] As used in this article, “containing,” “having,” or “including” includes “containing,” “mainly composed of,” “substantially composed of,” and “composed of”; “mainly composed of,” “substantially composed of,” and “composed of” are subordinate concepts of “containing,” “having,” or “including.”

[0075] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, and the reagents, methods and equipment used are conventional reagents, methods and equipment in this technical field.

[0076] Example 1: Preparation of recombinant type XVII collagen:

[0077] 1. Design of recombinant humanized type XVII collagen amino acid sequence:

[0078] SEQ ID No.1(Col17-1):GSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQGPKGQKGSVGDPGMEGPMGQRGREGPMGPRGEAGPPGSGEKGERGAAGEPGPHGPPGVPGSVGPKGSSGSPGPQGPPGPVGLQGLRGEVGLPGVKGDKGPMGPPGPKGDQGEKGPRGLTGEPGMRGLPGAVGEPGAKGAMGPAGPDGHQGPRGEQGLTGMPGIRGPPGPSGDPGKPGLTGPQGPQGLPGTPGRPGIKGEPGAPGKIGPPGPPGPRGPPGPSIPGPPGPRGPPGEGLPGPPGPPGSFGPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPPGQKGEMGTPGPKGDRGPAGPPGHPGPPGPRGHKGEKGDKGDQ;

[0079] SEQ ID No.2(Col17-2):GSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQGPKGQKGSVGDPGMEGPMGQRGREGPMGPRGEAGPPGSGEKGERGAAGEPGPHGPPGVPGSVGPKGSSGSPGPQGPPGPVGLQGLRGEVGLPGVKGDKGPMGPPGPKGDQGEKGPRGLTGEPGMRGLPGAVGEPGAKGAMGPAGPDGHQGPRGEQGLTGMPGIRGPPGPSGDPGKPGLTGPQGPQGLPGTPGRPGIKGEPGAPGKIGSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQGPKGQKGSVGDPGMEGPMGQRGREGPMGPRGEAGPPGSGEKGERGAAGEPGPHGPPGVPGSVGPKGSSGSPGPQGPPGPVGLQGLRGEVGLPGVKGDKGPMGPPGPKGDQGEKGPRGLTGEPGMRGLPGAVGEPGAKGAMGPAGPDGHQGPRGEQGLTGMPGIRGPPGPSGDPGKPGLTGPQGPQGLPGTPGRPGIKGEPGAPGKI;

[0080] SEQ ID No. 3 (Col17-3): GPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPPGQKGEMGTPGPKGDRGPAGPPGHPPGPGPRGHKGEKGDKGDQGPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPPGQKGEMGTPGPKGDRGPAGPPGHPPGPGPRGHKGEKGDKGDQGPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPPGQKGEMGTPGPKGDRGPAGPPGHPPGPGPRGHKGEKGDKGDQGPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPPGQKGEMGTPGPKGDRGPAGPPGHPPGPGPRGHKGEKGDQ;

[0081] SEQ ID No.4 (Col17-4): GPPGPPGPRGPGPGPGPGPGEGLPGPPGPGPGSFGPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPPGQKGEMGTPGPKGDRGPAGPPGHPPGPGPGRPGHKGEKDKGDQGPGPGPGPGPGPGPGPGPGPGPGPGPGPGEGLPGPPGPGSFGPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPPGQKGEMGTPGPKGDRGPAGPPGHPPGPGPGRPGHKGEKDKGDQGPGPGPGPGPGPGPGPGPGPGPGPGPGPGEGLPGPPGPGSFGPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPPGQKGEMGTPGPKGDRGPAGPPGHPPGPGPGRPGHKGEKDKGDQ;

[0082] SEQ ID No.5 (Col17-5): GHPGPQGPKGQKGSVGDPGMEGEAGPPGEKGERGAAGEPGPHGVKGDKGPMGPPGPKGDQGEKGPPGQKGEMGTPGPKGDRGPAGPPGHPGPPGHPGPQGPKGQKGSVGDPGMEGEAGPPGEKGERGAAGEPG PHGVKGDKGPMGPPPGPKGDQGEKGPPGQKGEMGTPPGPKGDRGPAGPPGHPGPPGHPGPQGPKGQKGSVGDPGMEGEAGPPGEKGERGAAGEPGPHGVKGDKGPMGPPGPKGDQGEKGPPGQKGEMGTPPGPKGDRGPAGPPGHPGPP.

[0083] 2. Gene Design and Synthesis: Based on the amino acid sequence of type XVII collagen screened in the previous stage, the gene sequence of type XVII collagen was determined. The gene was then synthesized by a gene synthesis company to obtain the nucleotide fragment encoding type XVII collagen.

[0084]

[0085]

[0086]

[0087]

[0088] SEQ ID NO.10 (COL17-5 gene sequence): GGTCATCCAGGTCCACAAGGTCCAAAGGGTCAAAAAGGTTCTGTTGGTGACCCAGGTATGGAAGGTGAAGCTGGTCCACCAGGTGAAAAAGGTGAAAGGGGTGCTGCTGGTGAACCAGGTCCTCATGGTGTTAAGGGTGATAAGGGTCCAATGGGTCCACCTGGTCCTAAAGGTGATCAAGGTGAAAAGGGACCTCCAGGTCAAAAGGGTGAGATGGGTACTCCAGGACCAAAAGGTGATAGAGGACCTGCTGGACCACCTGGACATCCTGGTCCTCCAGGACATCCAGGACCTCAGGGACCTAAAGGACAAAAAGGATCCGTTGGAGATCCTGGAATGGAAGGCGAGGCAGGACCTCCTGGTGAGAAAGGCGAACGTGGTGCAGCAGGCGAACCTGGACCACATGGTGTCAAAGGTGACAAAGGCCCTATGGGACCACCAGGACCTAAGGGTGACCAGGGCGAAAAAGGTCCTCCTGGCCAAAAAGGCGAAATGGGAACTCCCGGTCCTAAGGGCGATAGAGGTCCCGCTGGTCCTCCTGGTCATCCCGGTCCACCTGGACACCCCGGACCACAGGGTCCAAAAGGCCAGAAGGGATCTGTAGGCGATCCCGGCATGGAAGGTGAGGCCGGTCCTCCAGGCGAGAAGGGTGAGAGAGGTGCTGCAGGCGAGCCCGGTCCACACGGCGTAAAAGGCGACAAGGGACCAATGGGCCCTCCTGGACCAAAGGGCGACCAAGGTGAGAAGGGTCCACCAGGACAGAAAGGCGAGATGGGCACACCTGGTCCAAAGGGTGACAGAGGTCCAGCCGGACCACCAGGTCACCCAGGTCCTCCA。

[0089] 3. Construction of Recombinant Humanized Type XVII Collagen Expression Vectors: A suitable expression vector was selected. The plasmid vector used in this invention was pPIC9K. The synthesized target gene was ligated into the plasmid via multiple cloning sites (SnaBI and NotI), and a genomycin resistance gene was inserted simultaneously to construct recombinant expression plasmids, named KNCol17-1, KNCol17-2, KNCol17-3, KNCol17-4, and KNCol17-5, respectively. The constructed expression vectors were validated using sequencing to confirm that the target gene was correctly inserted into the vector and that the sequence was error-free.

[0090] 4. Transformation of host cells: The constructed recombinant expression vector was introduced into the host Pichia pastoris SMD1168 strain using an electroporation method. The specific procedures are as follows:

[0091] 4.1. The recombinant expression plasmids KNCol17-1, KNCol17-2, KNCol17-3, KNCol17-4, and KNCol17-5 were linearized by digestion with SacI enzyme at 37°C for 4 hours. The linearized products were purified and recovered using a kit (purchased from Shanghai Mygen Biotechnology Co., Ltd., product code D2111-02).

[0092] 4.2. Electroporation: Take 5 vials of SMD1168 competent cells (purchased from Beijing Cooler Labs Technology Co., Ltd., product number CC120), add 5 μg of linearized KNCol17-1, KNCol17-2, KNCol17-3, KNCol17-4, and KNCol17-5 products respectively, mix gently, transfer to a 0.2 cm electroporation cuvette that has been pre-chilled on ice, and incubate the electroporation cuvette and competent cells together on ice for 5 minutes. Cells were electroporated using the Pichia pastoris electroporation program provided with the electroporator (electroporator and electroporation cuvette purchased from Bio-Rad, model: 1652660. The electroporator program was set to "Pic". The electroporation cuvette was placed into the electroporation chamber slide. The slide was pushed into the electroporation chamber until the electroporation cuvette was fixed between the contact electrodes of the electroporation chamber. Electroporation was performed once. The electroporation cuvette was removed from the electroporation chamber. The pulse parameters were checked and recorded. The time constant should be close to 5 ms). Then, 1 mL of pre-chilled 1M sorbitol was quickly added, and the contents were transferred to a sterile 1.5 mL centrifuge tube. 200 μL of electroporated cells were spread onto MD plates and incubated upside down in a 30°C incubator for 2-3 days until single colonies appeared.

[0093] 5. Screening for positive strains: Pick a single colony from the transformation plate and place it in 50 μL of TE buffer. Disrupt the cells (heat at 100°C for 10 minutes, then incubate on ice for 10 minutes) before PCR identification. Design PCR primers on the pPIC9K expression vector (upstream primer P1: TACTATTGCCAGCATTGCTGC; downstream primer P2: GCAAATGGCATTCTGACATCC). Detect the PCR results by nucleic acid electrophoresis to confirm positive colonies.

[0094] PCR reaction system: 14.6 μL ddH2O, 2 μL 10×Easytaq buffer, 0.4 μL dNTP Mix (10 μM), 0.4 μL upstream primer P1 (10 μM), 0.4 μL downstream primer P2 (10 μM), 0.2 μL EasyTaq, and 2 μL bacterial template. The PCR reaction procedure is shown in Table 1.

[0095] Table 1 PCR reaction procedure

[0096]

[0097] The results of nucleic acid electrophoresis detection of PCR products are as follows: Figure 1 As shown, M: DNA Marker; 1: KNCol17-1; 2: KNCol17-2; 3: KNCol17-3; 4: KNCol17-4; 5: KNCol17-5.

[0098] 6. Screening of high-copy strains: Positive transformants were selected from MD plates and inoculated into 3 mL of YPD liquid medium, incubated at 30°C and 240 rpm for 24 h. After centrifugation to remove the supernatant, the transformed strain was inoculated into 3 mL of YPD medium with an initial concentration of 0.5 mg / mL of genimycin, and incubated at 30°C and 240 rpm for 24 h. After centrifugation to remove the supernatant, the transformed strain was inoculated into 3 mL of YPD medium containing 1 mg / mL genimycin, and incubated at 30°C and 240 rpm for 24 h. After centrifugation to remove the supernatant, the transformed strain was inoculated into 3 mL of YPD medium containing 2 mg / mL genimycin, and incubated at 30°C and 240 rpm for 24 h. After centrifugation to remove the supernatant, the transformed strain was inoculated into 3 mL of YPD medium containing 4 mg / mL genimycin, and incubated at 30°C and 240 rpm for 24 h. When the OD600 of the bacterial culture reached 1.0, the culture was diluted 1000 times, and 100 μL was plated onto YPD plates containing 4 mg / mL genimycin and incubated at 30°C for 2-3 days. Strains that can grow on 4 mg / mL genimycin plates are identified as high-copy collagen strains.

[0099] 7. Recombinant humanized type XVII collagen expression: The collagen high-copy strain was induced and cultured in shake flasks. The protein expression level was detected after 72 h of induction with 1% methanol. The collagen expression yield was detected by SDS-PAGE to confirm the collagen high-expression strain.

[0100] See results Figure 2 (M: protein marker; 1: KNCol17-1; 2: KNCol17-2; 3: KNCol17-3; 4: KNCol17-4; 5: KNCol17-5) KNCol17-5 had the highest yield in shake flasks and no obvious degradation bands during expression, indicating that the expression product of strain KNCol17-5 is stable and not easily degraded.

[0101] like Figure 3 As shown, grayscale analysis was performed using ImageJ software. The expression levels of KNCol17-1, KNCol17-2, KNCol17-3, KNCol17-4, and KNCol17-5 strains in shake flasks were 0.12 g / L, 0.21 g / L, 0.17 g / L, 0.18 g / L, and 0.35 g / L, respectively.

[0102] Example 2: The second nucleic acid molecule promotes the expression of recombinant type XVII collagen:

[0103] 1. Construction of a recombinant humanized type XVII collagen expression vector containing a second nucleic acid molecule: The PGAPZαA plasmid was selected as the expression vector. The α factor signal peptide was removed by restriction enzyme sites (BstBⅠ and EcoRⅠ). At the same time, the synthesized target genes KAR2, HAC1, ERO1, PDI1, WSC4, ERV29, Sec1, Sly1, SSA4(Sc), SSE1(Sc), KIN2 or CUP5 were respectively linked to the GAP promoter of the PGAPZαA plasmid to construct the recombinant expression plasmid. They are named KAR2-pGAPZA (SEQ ID NO.11), HAC1-pGAPZA (SEQ ID NO.12), ERO1-pGAPZA (SEQ ID NO.13), PDI1-pGAPZA (SEQ ID NO.14), WSC4-pGAPZA (SEQ ID NO.15), ERV29-pGAPZA (SEQ ID NO.16), Sec1-pGAPZA (SEQ ID NO.17), Sly1-pGAPZA (SEQ ID NO.18), SSA4(Sc)-pGAPZA (SEQ ID NO.19), SSE1(Sc)-pGAPZA (SEQ ID NO.20), KIN2-pGAPZA (SEQ ID NO.21), CUP5-pGAPZA (SEQ ID NO.22), SEQ ID NO.11-SEQ ID NO.22 are detailed in the sequence listing. The constructed expression vector was validated by sequencing to confirm that the target gene was correctly inserted into the vector and that the sequence was error-free.

[0104] 2. Transformation of KNCol17-5 host strain: The constructed expression vector was introduced into the host KNCol17-5 strain using an electroporation method. The specific steps are as follows:

[0105] 2.1. The recombinant expression plasmids KAR2-pGAPZA, HAC1-pGAPZA, ERO1-pGAPZA, PDI1-pGAPZA, WSC4-pGAPZA, ERV29-pGAPZA, Sec1-pGAPZA, Sly1-pGAPZA, SSA4(Sc)-pGAPZA, SSE1(Sc)-pGAPZA, KIN2-pGAPZA, and CUP5-pGAPZA were linearized by digestion with AvrII enzyme at 37°C for 4 hours. The linearized products were then purified and recovered using a kit (purchased from Shanghai Maigen Biotechnology Co., Ltd., product code D2111-02).

[0106] 2.2. Preparation of KNCol17-5 competent cells: Inoculate 50 ml of liquid YPD medium into a 250 ml conical tube, pick a single colony of KNCol17-5, and incubate at 240 rpm at 30°C until the OD600 reaches 1.3-1.5. Centrifuge at 4°C (1500 g, 5 min) to collect the bacterial culture, and resuspend the precipitate in 50 ml of ice-cold sterile water. Centrifuge at 4°C (1500 g, 5 min) to collect the bacterial culture, and resuspend the precipitate in 40 ml of ice-cold sterile water. Centrifuge at 4°C (1500 g, 5 min) to collect the bacterial culture, and resuspend the precipitate in 20 ml of ice-cold 1M sorbitol solution. Centrifuge at 4°C (1500 g, 5 min) to collect the bacterial culture, add 2 ml of ice-cold 1M sorbitol solution to resuspend the precipitate, and aliquot into 1.5 ml centrifuge tubes at 100 μL / tube to obtain KNCol17-5 competent cells.

[0107] 2.3. Electroporation: Take 12 KNCol17-5 competent cells and add 5 μg of linearized KAR2-pGAPZA, HAC1-pGAPZA, ERO1-pGAPZA, PDI1-pGAPZA, WSC4-pGAPZA, ERV29-pGAPZA, Sec1-pGAPZA, Sly1-pGAPZA, SSA4(Sc)-pGAPZA, SSE1(Sc)-pGAPZA, KIN2-pGAPZA, and CUP5-pGAPZA products respectively. Mix gently and transfer to a pre-chilled 0.2 cm electroporation cuvette. Incubate the cuvette and competent cells together on ice for 5 minutes. Electroporate the cells using the same program as in Example 1, then quickly add 1 mL of pre-chilled 1 M sorbitol and transfer the contents to a sterile 1.5 mL centrifuge tube. Spread 200 μL of electroporated cells onto a YPD plate containing 100 μg / mL bleomycin. Incubate the YPD plate upside down in a 30°C incubator for 2-3 days until single clones appear.

[0108] 3. Screening for positive strains: Single colonies from transformation plates were picked and placed in 50 u LTE buffer. The cells were lysed (heated at 100°C for 10 minutes, then placed on ice for 10 minutes) before PCR identification. PCR primers were designed on the pGAPZA expression vector (upstream primer P3: CAATTGAACAACTATTTCGAA; downstream primer P4: GGCATTCTGACATCCTCTTGA). Nucleic acid electrophoresis was used to detect the PCR results, confirming positive colonies.

[0109] PCR reaction system: 14.6 μL ddH2O, 2 μL 10×Easytaq buffer, 0.4 μL dNTP Mix (10 μM), 0.4 μL upstream primer P3 (10 μM), 0.4 μL downstream primer P4 (10 μM), 0.2 μL EasyTaq, and 2 μL bacterial template. The PCR reaction procedure is shown in Table 2.

[0110] Table 2 PCR reaction procedure

[0111]

[0112] The results of nucleic acid electrophoresis detection of PCR products are as follows: Figure 4 shown, where M: DNA Marker; 1: KAR2-pGAPZA; 2: HAC1-pGAPZA; 3: ERO1-pGAPZA; 4: PDI1-pGAPZA; 5: WSC4-pGAPZA; 6: ERV29-pGAPZA; 7 : Sec1-pGAPZA; 8: Sly1-pGAPZA; 9: SSA4(Sc)-pGAPZA; 10: SSE1(Sc)-pGAPZA; 11: KIN2-pGAPZA; 12: CUP5-pGAPZA.

[0113] 4. Screening of high-copy strains: Positive transformants were selected from YPD plates and inoculated into 3 mL of YPD liquid medium, incubated at 30°C and 240 rpm for 24 h. After centrifugation to remove the supernatant, the transformants were inoculated into 3 mL of YPD medium containing 500 μg / mL bleomycin, and incubated at 30°C and 240 rpm for 24 h. After centrifugation to remove the supernatant, the transformants were inoculated into 3 mL of YPD medium containing 1 mg / mL bleomycin, and incubated at 30°C and 240 rpm for 24 h. After centrifugation to remove the supernatant, the transformants were inoculated into 3 mL of YPD medium containing 2 mg / mL bleomycin, and incubated at 30°C and 240 rpm for 24 h. After centrifugation to remove the supernatant, the transformants were inoculated into 3 mL of YPD medium containing 4 mg / mL bleomycin, and incubated at 30°C and 240 rpm for 24 h. When the bacterial suspension has an OD600 of 1.0, dilute it 1000 times, then take 100 μL and plate it onto a YPD plate containing 4 mg / mL bleomycin, and incubate at 30°C for 2-3 days. Select strains that can grow on the 4 mg / mL bleomycin plate; these are considered high-copy strains.

[0114] 5. Protein expression induction: High-copy strains were cultured in shake flasks for induction. The protein expression level was detected after 72 h of induction with 1% methanol. The collagen expression yield was detected by SDS-PAGE to confirm the effect of different second nucleic acid molecules on collagen expression.

[0115] The results are as followsFigure 5 (M: Protein Marker; 1: KNCol17-5; 2: KAR2-pGAPZA; 3: HAC1-pGAPZA; 4: ERO1-pGAPZA; 5: PDI1-pGAPZA; 6: WSC4-pGAPZA; 7: ERV29-pGAPZA; 8: Sec1-pGAPZA; 9: Sly1-pGAPZA; 10: SSA4(Sc)-pGAPZA; 11: SSE1(Sc)-pGAPZA; 12: KIN2-pGAPZA; 13: CUP5-pGAPZA) As shown, KIN2-pGAPZA had the highest yield in shake flasks.

[0116] like Figure 6 As shown, grayscale analysis was performed using ImageJ software. The expression level of KNCol17-5 in the control group was 0.32 g / L. KAR2-pGAPZA, Sec1-pGAPZA, Sly1-pGAPZA, PDI1-pGAPZA, WSC4-pGAPZA, ERV29-pGAPZA, HAC1-pGAPZA, ERO1-pGAPZA, and SSA4(Sc)- were also observed. The expression levels of pGAPZA, SSE1(Sc)-pGAPZA, KIN2-pGAPZA, and CUP5-pGAPZA strains in shake flasks were 0.38 g / L, 0.58 g / L, 0.98 g / L, 0.22 g / L, 0.33 g / L, 0.15 g / L, 0.24 g / L, 0.18 g / L, 0.45 g / L, 0.52 g / L, 1.22 g / L, and 0.49 g / L, respectively. KIN2-pGAPZA showed the highest yield in shake flasks, with a 3.8-fold increase in expression compared to the control group KNCol17-5, indicating that KIN2 significantly promotes the expression of recombinant humanized type XVII collagen.

[0117] 6. Identification of the structure of recombinant type XVII collagen: Circular dichroism spectroscopy is a spectroscopic method used to determine the structure of compounds with chiral structures that produce differential absorption between left and right rotation. It is mainly used to determine the asymmetry of molecular structures. Most biological macromolecules contain chiral groups and structures; therefore, circular dichroism spectroscopy is often used to measure and observe changes in the structure and conformation of biological macromolecules. The circular dichroism spectrum of the triple helix structure of collagen generally shows a positive absorption peak near 221 nm and a negative absorption peak near 195 nm (industry standard YY / T1849—2022).

[0118] The strain transfected with KIN2-pGAPZA was fermented and purified according to the method described in the literature (Reference: [1] Yu Haiwen. (2025). Fermentation and secretion expression of human type XVII collagen by recombinant Pichia pastoris and its purification (Master's thesis, Yantai University). Master's thesis https: / / link.cnki.net / doi / 10.27437 / d.cnki.gytdu.2025.000746doi:10.27437 / d.cnki.gytdu.2025.000746. The full text of which is incorporated herein by reference), to obtain lyophilized recombinant type XVII collagen. The lyophilized product was dissolved in 20 mM PB buffer (pH 7.4) to make the concentration of recombinant type XVII collagen 0.5 mg / mL. The sample was transferred to the 10mm×10mm sample cell of the circular dichroism chromatograph. The scanning wavelength range was set to 190nm-260nm, the scanning speed to 100nm / min, and the scanning temperature to 4℃.

[0119] The results are as follows Figure 7 As shown, recombinant type XVII collagen has a positive absorption peak at 221 nm and a negative peak at 195 nm. Based on the known circular dichroism chromatographic characteristics of the triple helix structure of collagen, it is determined that the collagen sample has a triple helix structure.

[0120] 7. Cell Scratch Assay for the Repair Function of Recombinant Type XVII Collagen: When recombinant collagen is used for tissue repair and reconstruction, it should facilitate cell recognition and migration. The cell migration assay should be performed according to Appendix C of (Industry Standard YY / T1849—2022). The cell scratch assay is a simple method for measuring cell migration. On a monolayer of adherent cells cultured in an in vitro culture dish or plate, a line is drawn in the central area of ​​cell growth using a micropipette tip or other hard object. The cells in the central part are removed, and the cells are cultured again until the set experimental time is observed. Whether the peripheral cells migrate to the central scratch area is then observed, thereby determining the cell's growth and migration ability.

[0121] The lyophilized recombinant type XVII collagen was dissolved in PBS buffer to achieve a concentration of 0.5 mg / mL. The control group was prepared using PBS buffer. Results are as follows: Figure 8 As shown, after cell scratching, treatment with recombinant type XVII collagen for 24 hours resulted in a cell migration rate of 95%, while the control group showed a cell migration rate of only 45%, indicating that recombinant type XVII collagen has the function of promoting cell repair.

[0122] It should be noted that, in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Without further limitations, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes said element.

[0123] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A recombinant type XVII collagen, characterized in that, The amino acid sequence is shown in SEQ ID No.

5.

2. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes the recombinant type XVII collagen as described in claim 1.

3. The nucleic acid molecule according to claim 2, characterized in that, The nucleic acid molecule in question is DNA.

4. The nucleic acid molecule according to claim 3, characterized in that, The nucleotide sequence of the DNA is shown in SEQ ID NO.

10.

5. A carrier, characterized in that, The vector comprises the nucleic acid molecule as described in any one of claims 2-4.

6. The carrier according to claim 5, characterized in that, The vectors include viral vectors and / or non-viral vectors.

7. The carrier according to claim 6, characterized in that, The carrier is a non-viral carrier.

8. The carrier according to claim 7, characterized in that, The non-viral vector is a DNA plasmid.

9. The carrier according to claim 8, characterized in that, The DNA plasmid also includes a second nucleic acid molecule.

10. The carrier according to claim 9, characterized in that, The second nucleic acid molecule is selected from nucleic acid molecules encoding KAR2, WSC4, Sec1, Sly1, SSA4, SSE1, KIN2, or CUP5.

11. The carrier according to claim 10, characterized in that, The second nucleic acid molecule is selected from nucleic acid molecules encoding KAR2.

12. A cell, characterized in that, The cell comprises the nucleic acid molecule of any one of claims 2-4 and / or the vector of any one of claims 5-11.

Citation Information

Patent Citations

  • Recombinant humanized III-type collagen as well as genetically engineered bacterium and expression method thereof

    CN118878666A

  • Recombinant pichia pastoris genetically engineered bacterium for expressing recombinant full-chain-length humanized collagen as well as preparation method and application of recombinant pichia pastoris genetically engineered bacterium

    CN120118766A